{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-345733","form_type":"8-K","ticker":"STRO","cik":"0001382101","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2026-08-12T11:15:23+00:00","discovered_at":"2026-08-12T11:20:00.474422+00:00","generated_at":"2026-08-12T11:20:14.009874+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Sutro Q2 revenue drops to $9.8M from $63.7M; STRO-004 shows early responses","bullets":["Revenue $9.8M vs $63.7M in Q2 2025; cash $164.3M vs $202.6M at March 31, 2026.","STRO-004 Phase 1: confirmed and unconfirmed partial responses in pancreatic, head/neck, NSCLC at 3-4 mg/kg; discontinuation rate 6%.","STRO-004 PK: half-life ~7 days, DAR8 preserved, 25-50% more ADC exposure with 50% less payload vs conventional.","STRO-006 Phase 1 start expected Q3 2026; STRO-227 IND on track for 2026.","Astellas collaboration: $10M milestone received April 2026; second iADC program to enter clinic by end 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-345733","json":"https://secwatch.observer/filing/0001193125-26-345733.json","markdown":"https://secwatch.observer/filing/0001193125-26-345733.md","text":"https://secwatch.observer/filing/0001193125-26-345733.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382101/000119312526345733/0001193125-26-345733-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382101/000119312526345733/stro-20260812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T11:20:14.009874+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}